If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma highlights Innovative Drug Delivery Solutions at CPhI Europe

    Quick Contact
    • Aptar Pharma
    Aptar Pharma highlights Innovative Drug Delivery Solutions at CPhI Europe
    Europe, Iberia, Spain, Beauty, Personal Care, Personal Care, Eye Care, Health, Pharmaceuticals, Primary Packaging, Dispensing Closures, Pumps, Sprays, Drug Delivery Devices, Active, Smart Packaging, Sustainable Packaging, Recyclable Packaging, Shows, Associations, Media, Packaging Trade Shows, Events, CPhI

    Aptar Pharma highlights Innovative Drug Delivery Solutions at CPhI Europe

    Aptar Pharma is delighted to announce its participation in the highly anticipated CPhI Europe event, scheduled to take place from October 24th to 26th, 2023, in Barcelona, Spain. As a leading provider of advanced drug delivery systems and solutions, we will present our diverse portfolio of products, including components, active packaging, and digital health solutions, at booth number #2K40.

    At the Aptar Pharma booth, attendees will have the opportunity to explore the latest breakthroughs in drug delivery systems across various routes, such as nasal, pulmonary, eye care, injectables, and dermal. Through these cutting-edge innovations, we aim to enhance patient experiences.

    Key highlights of Aptar Pharma’s presence at CPhI Europe include:

    1. Commitment to Sustainability: Aptar Pharma is dedicated to delivering a more sustainable future, offering solutions that support a circular approach to healthcare.
    2. APF Futurity™: Aptar Pharma will unveil APF Futurity™, its groundbreaking metal-free and highly recyclable spray pump for nasal spray devices. This innovation reflects Aptar Pharma’s dedication to designing environmentally friendly solutions.
    3. Expanded Capacity and Capabilities: Aptar Pharma is expanding its operations worldwide to meet the growing demands of its injectables The expansion aims to increase capacity and introduce new capabilities to better serve pharmaceutical partners.
    4. Advancements in Pressurized Metered Dose Inhalers: Aptar Pharma is at the forefront of developing sustainable pressurized metered dose inhalers (pMDIs) with end-to-end solutions. These advancements contribute to reducing environmental impact while ensuring optimal drug delivery.
    5. Aptar Pharma Services: Aptar Pharma supports its customers in accelerating and derisking their drug development journey, from formulation to patient, through its comprehensive Aptar Pharma Services.
    6. Aptar Digital Health: Aptar Pharma provides continuous support and decentralized care to enhance patient experiences through Aptar Digital Health solutions.

    In addition, Aptar CSP Technologies, a division of Aptar Pharma, will showcase its extensive portfolio of active material science solutions for protecting drug delivery systems. Experts will be available to discuss Aptar CSP’s Co-Development Program, which aims to accelerate and de-risk the drug development process.

    To gain exclusive early access to the exhibition halls, interested individuals can register online and receive a Free Early Access Pass. Use Promo Code FOCX1563 at checkout to secure this limited opportunity.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 17 May 2023
    • Hits 350
    Sun-Rain
    APG
    Epopack